camptothecin has been researched along with bn 80927 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigg, DC; Coulomb, H; Demarquay, D; Harnett, J; Huchet, M; Lanco, C; Lavergne, O; Lesueur-Ginot, L; Rolland, A | 1 |
| Bigg, D; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Lavergne, O; Lesueur-Ginot, L | 1 |
| Bigg, D; Carlson, M; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, P; Lauer, J; Lavergne, O | 1 |
| Bigg, DC; Camara, J; Coulomb, H; Demarquay, D; Huchet, M; Kasprzyk, PG; Lavergne, O; Lesueur-Ginot, L; Prévost, G | 1 |
| Yang, S; Zhang, WN | 1 |
| Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF | 1 |
1 review(s) available for camptothecin and bn 80927
| Article | Year |
|---|---|
[Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2004 |
1 trial(s) available for camptothecin and bn 80927
| Article | Year |
|---|---|
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
4 other study(ies) available for camptothecin and bn 80927
| Article | Year |
|---|---|
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Topics: Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Catalysis; Enzyme Inhibitors; Etoposide; Humans; Irinotecan; Nucleic Acid Synthesis Inhibitors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2000 |
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Enzyme Inhibitors; Growth Inhibitors; Humans; Irinotecan; Male; Mice; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Drug Screening Assays, Antitumor; Drug Stability; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2004 |